|
|
[½»Á÷]
ÔÚÑп¹°¢¶û´Äº£Ä¬²¡Ò©Îï¼°Êг¡·ÖÎö ÒÑÓÐ13È˲ÎÓë
1.ÉÏÊп¹°¢¶û´Äº£Ä¬²¡Ò©Îï
ĿǰFDAÅú×¼µÄ¿¹°¢¶û´Äº£Ä¬²¡Ò©ÎïÓÐÎå¸ö£¬·Ö±ðÊǶàÄÎßßÆë£¨Donepezil£©¡¢Àû˹µÄÃ÷£¨Rivastigmine£©¡¢¼ÓÀ¼ËûÃô£¨Galantamine£©¡¢Ëû¿ËÁÖ£¨Tacrine£©¡¢ÃÀ½ð¸Õ£¨Memantine£©£¬ÆäÖÐǰËĸö¶¼Êǵ¨¼îõ¥Ã¸£¨AChE£©ÒÖÖÆ¼Á£¬ÃÀ½ð¸ÕÊÇNMDAÊÜÌåÞ׿¹¼Á¡£ÕâЩҩÎï¶¼ÊÇÖα겻Öα¾µÄ£¬ÁÆÐ§²»ÏÔÖø£¬Ö»ÄÜ¿ØÖÆ»ò¸ÄÉÆÈÏÖªºÍ¹¦ÄÜÖ¢×´6-12¸öÔ£¬²»ÄÜ×èÖ¹»òÏÔÖøÑÓ»º²¡Çé¶ñ»¯¡£
2.ÔÚÑп¹°¢¶û´Äº£Ä¬²¡Ò©Îï
Ŀǰ¿Û³ý´óѧºÍ¹«¹²Ñо¿ÏîÄ¿£¬¹²ÓÐ102¸ö¿¹°¢¶û´Äº£Ä¬²¡Ò©Îï´¦ÓÚÁÙ´²£¬Ö÷Òª×÷ÓÃÓÚÉñ¾ÐźÅͨ·ºÍA¦Âµí·ÛÑùµ°°×°ß¡£×÷ÓÃÓÚÉñ¾ÐźÅͨ·µÄ°üÀ¨nAChRÞ׿¹¼Á¡¢AChEÒÖÖÆ¼Á¡¢5-HT4¼¤¶¯¼Á»ò5-HT6Þ׿¹¼Á¡¢mAChR¼¤¶¯¼Á¡¢×é°·H3ÊÜÌåÞ׿¹¼ÁµÈ¡£ÕâЩҩÎïÁÙ´²¼°Êг¡Ç°¾°ÓÐÏÞ£¬Ä¿Ç°Ã»ÓÐÁÙ´²ÊÔÑé±íÃ÷ÓÅÓÚÒÑÉÏÊÐÒ©Îï¡£
Ò»¸ö±È½ÏÒýÈËעĿµÄÒ©ÎïÊÇÑǼ×À¶£¨Methylthionine, TRx0237, LMTX£©£¬×÷ΪTauµ°°×¾Û¼¯ÒÖÖÆ¼Á£¬Ä¿Ç°ÒѽøÈëIIIÆÚÁÙ´²Ñо¿£¬IIÆÚÁÙ´²Êý¾ÝÏÔʾÄÜÏÔÖøÑÓ»ºÇá¶ÈÖÁÖжȰ¢¶û´Äº£Ä¬²¡¶ñ»¯¡£
![]()
ÔÚ½øÈëÁÙ´²Ñо¿µÄºòѡҩÎïÖУ¬31¸ö·Ö×Ó°ÐÏòA¦Â£¨ÒÖÖÆA¦Â¾ÛºÏ¡¢´Ù½øA¦ÂÇå³ý£©ºÍA¦Â´úл£¨¦Á-·ÖÃÚø¼¤»î¼Á¡¢¦Â-·ÖÃÚøÒÖÖÆ¼Á¡¢¦Ã-·ÖÃÚøÒÖÖÆ¼Á£©£¬ÆäÖÐAvagacestat£¨¦Ã-·ÖÃÚøÒÖÖÆ¼Á£©¡¢LY-2886721£¨¦Â-·ÖÃÚøÒÖÖÆ¼Á£©¡¢MK-8931£¨¦Â-·ÖÃÚøÒÖÖÆ¼Á£©¾ù´¦ÓÚIIÆÚÁÙ´²¡£
´Ù½øA¦ÂÇå³ý¼´ÃâÒßÁÆ·¨£¬Ä¿Ç°ÓÐ22¸ö´¦ÓÚÁÙ´²£¬°üÀ¨Ö÷¶¯ÃâÒߣ¨ÒßÃ磩ºÍ±»¶¯ÃâÒߣ¨¿¹Ì壩¡£µÚ¶þ´úA¦ÂÒßÃç°üÀ¨ACC-001¡¢AD02¡¢CAD106£¬ËûÃǶ¼º¬ÓÐA¦ÂË鯬£¬ÉÏÓÐBϸ°û¿¹Ô¾ö¶¨´Ø£¬Í¬Ê±±ÜÃâÁ˵ÚÒ»´úÒßÃçAN-1792¼¤»îTϸ°ûÒýÆðÄÔĤÑ׵ĸ±×÷Óã¨AN-1792ÒÑÓÚ2002ÄêÖÐÖ¹ÁÙ´²£©¡£
![]()
ÔÚ2012Ä꣬Á½¸ö±»¶¯ÃâÒßÒ©Îµ¥¿Ë¡¿¹Ì壩µÄÁÙ´²½á¹û½ÒÏþ£¬BapineuzumabºÍSolanezumab¶¼Î´ÄÜ´ïµ½Ö÷ÒªÁÙ´²Öյ㣬µ«SolanezumabÏÔʾ³öκ͵Äͳ¼ÆÑ§ÉÏÓÐЧµØÑÓ»ºÈÏÖª¹¦ÄÜϽµ¡£ÓÉÓÚÁÆÐ§Çá΢£¬ÇÒ´æÔÚѪ¹ÜÔ´ÐÔÄÔË®Ö×·çÏÕ£¬BapineuzumabºÍSolanezumabǰ¾°¿°ÓÇ¡£ÔÚ²¡ÈËÄÔÄÚ³öÏÖA¦Âµí·ÛÑùµ°°×°ßºóÕë¶ÔA¦Â½øÐÐÖÎÁÆ»òÐíÒѾ̫³Ù£¬µ«ÕâЩʧ°Ü²¢²»±íʾA¦ÂÀíÂÛÓÐÎ󡣯äËû±»¶¯ÃâÒßÒ©ÎﻹÓÐGammagard£¨IIIÆÚÁÙ´²£©¡¢Gantenerumab£¨IIIÆÚÁÙ´²£©¡¢Crenezumab£¨IIÆÚÁÙ´²£©¡£
½üÄêÔÚ¿¹°¢¶û´Äº£Ä¬²¡ÁìÓòÀï³Ì±®Ê½½øÕ¹µ±Êô֢״ǰÕï¶Ï£¬2012ÄêFDAÅú×¼ÁËEli LillyµÄFlorbetapir F18 £¨ÉÌÆ·ÃûAmyvid£©£¬×¢Éäºó½øÐÐPETɨÃ裬¼ì²â»¼ÕßÄÔÄڵĦÂ-µí·ÛÑùµ°°×°ß¡£ÅäºÏÕï¶ÏÊÔ¼Á£¬Ó¦Óõ¥¿¹ÔçÆÚÖÎÁÆ¿ÉÄÜÓÐÏÔÖøÐ§¹û£¬µ«Äõ½×îÖյĽáÂÛÐÔÊý¾Ý¿ÉÄÜÒªÔÚÈýÎåÄêÖ®ºó¡£
3.Êг¡·ÖÎö
ÔÚδÀ´6Ä꣬¼´Ê¹Gammagard»òFDAÅú×¼£¬¿¹°¢¶û´Äº£Ä¬²¡Ò©ÎïÊг¡½«³ÊÏÖϽµÇ÷ÊÆ£¬ ´Ó2012ÄêµÄ42ÒÚÃÀԪϽµÖÁ2018ÄêµÄ38ÒÚÃÀÔª£¬ÕâÊÇÒòΪÖ÷ÒªÉÏÊп¹°¢¶û´Äº£Ä¬²¡Ò©ÎïרÀû¼´½«µ½ÆÚ¡£»òÐíÔçÕï¶ÏÔçÖÎÁÆÕýÊǹ¥¿Ë°¢¶û´Äº£Ä¬²¡µÄÏ£Íû£¬µ«Òª³ÉΪÏÖʵ¿ÖÅÂÊÇ5ÄêÄËÖÁ10ÄêÒÔºóÁË¡£
Ref: Nat Rev Drug Discov. 2013, 12(1), 19-20.
[ Last edited by ³ÕÃÎäìÏæ on 2013-3-13 at 01:06 ] |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
» ²ÂÄãϲ»¶
|